<DOC>
	<DOCNO>NCT00812799</DOCNO>
	<brief_summary>This study perform determine long-term efficacy 19.000 BU Oralgen grass pollen administer daily patient grass pollen related allergic rhinoconjunctivitis .</brief_summary>
	<brief_title>A Randomised , Double-blind , Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis</brief_title>
	<detailed_description>Patients 18 60 year randomize receive either Oralgen grass pollen placebo administer sublingually day . Treatment start least 16 week prior anticipated start pollen season 2009 last end pollen season 2011 . Study medication titrate first period treatment maintenance dose reach .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>male female grass pollen relate rhinoconjunctivitis symptom least last 2 pollen season positive skin prick test RRTSS great equal 12 2008 season sign informed consent positive skin prick test environmental allergen suffer serious allergic symptom clinical history significant symptomatic allergic rhinitis due tree/weed pollen potentially overlap grass pollen season clinical history symptomatic perennial allergic rhinitis cause allergen patient regularly expose lack good health abnormal spirometry lower respiratory tract infection asthma require treatment beta2 agonists oral steroid within 12 week screen regular contraindication use immunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>randomise</keyword>
	<keyword>double-blind</keyword>
	<keyword>placebo-controlled</keyword>
	<keyword>efficacy safety</keyword>
	<keyword>OralgenÂ® Grass Pollen</keyword>
	<keyword>allergic rhinoconjunctivitis</keyword>
	<keyword>allergy</keyword>
	<keyword>rhinoconjunctivitis</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>grass pollen extract</keyword>
</DOC>